Our top pick for
Beginners
Finder Award
argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx NV ADR employs 650 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in argenx NV ADR
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARGX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
argenx NV ADR stock price (NASDAQ: ARGX)
Use our graph to track the performance of ARGX stocks over time.argenx NV ADR shares at a glance
Information last updated 2022-06-24.
| Latest market close | $373.58 |
|---|---|
| 52-week range | $249.50 - $365.81 |
| 50-day moving average | $316.72 |
| 200-day moving average | $304.94 |
| Wall St. target price | $390.74 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-11.53 |
Buy argenx NV ADR shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.1 - 6 of 6
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy argenx NV ADR stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
argenx NV ADR price performance over time
Historical closes compared with the close of $373.58 from 2022-06-29
| 1 week (2022-06-23) | 2.48% |
|---|---|
| 1 month (2022-05-27) | 15.62% |
| 3 months (2022-03-30) | 19.17% |
| 6 months (2021-12-30) | 5.82% |
| 1 year (2021-06-30) | 24.08% |
|---|---|
| 2 years (2020-06-30) | 65.87% |
| 3 years (2019-06-28) | 163.86% |
| 5 years (2017-06-30) | 1,661.34% |
argenx NV ADR financials
| Revenue TTM | $381.2 million |
|---|---|
| Gross profit TTM | $-52,254,000 |
| Return on assets TTM | -8.77% |
| Return on equity TTM | -19.4% |
| Profit margin | -156.1% |
| Book value | $49.05 |
| Market capitalisation | $19.8 billion |
TTM: trailing 12 months
argenx NV ADR share dividends
We're not expecting argenx NV ADR to pay a dividend over the next 12 months.
argenx NV ADR share price volatility
Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $249.5 up to $365.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 1.0263. This would suggest that argenx NV ADR's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
argenx NV ADR overview
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S. À. R.
Frequently asked questions
What percentage of argenx NV ADR is owned by insiders or institutions?Currently 0.002% of argenx NV ADR shares are held by insiders and 62.878% by institutions. How many people work for argenx NV ADR?
Latest data suggests 650 work at argenx NV ADR. When does the fiscal year end for argenx NV ADR?
argenx NV ADR's fiscal year ends in December. Where is argenx NV ADR based?
argenx NV ADR's address is: Willemstraat 5, Breda, Netherlands, 4811 AH What is argenx NV ADR's ISIN number?
argenx NV ADR's international securities identification number is: US04016X1019 What is argenx NV ADR's CUSIP number?
argenx NV ADR's Committee on Uniform Securities Identification Procedures number is: 04016X101
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert